Firm Secures Duty-Free Treatment for HIV Drug

On February 6, 2020, the Firm secured duty-free treatment for a Fortune 50 pharmaceutical company's subsidiary for an HIV drug. The U.S. Court of International Trade ruled that the drug, which comes from Ireland and Switzerland, should enter the U.S. duty-free because the drug fits within the criteria of the pharmaceutical appendix to the U.S. tariff code that allows certain drugs to enter the U.S. without duty payment.

To read press on the win, click here.